Skip to main content
Evidence Snapshot

Structural capsid protein

CHEMBL2366504 SINGLE PROTEIN Human immunodeficiency virus 1
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T13:45:33Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2366504
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Structural capsid protein as ChEMBL target CHEMBL2366504, mapped to UniProt Q76129. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Structural capsid protein
SINGLE PROTEIN · Human immunodeficiency virus 1
As of 2026-09-13
ChEMBL target ID
CHEMBL2366504
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q76129
Structural capsid protein
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Structural capsid protein matters

As of 2026-09-13

Structural capsid protein is reviewed as Structural capsid protein (UniProt Q76129); Structural capsid protein shows approved-linked disease relevance led by HIV infection. 3 more disease programs remain visible in the same review block.; 2 linked drugs keep this evidence frame grounded.; the current evidence base includes 1 approved drug, 212 compounds, and 61 assays, with lead potency reaching pChEMBL 10.3.

Disease context
HIV infection

Structural capsid protein shows approved-linked disease relevance led by HIV infection. 3 more disease programs remain visible in the same review block. 2 linked drugs keep the rationale reviewable. 3 additional disease programs remain visible in the same card. Linked drugs include LENACAPAVIR, LENACAPAVIR SODIUM.

Start review with HIV infection because it currently carries approved-linked support. Linked drugs include LENACAPAVIR, LENACAPAVIR SODIUM. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 2 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 1 approved drug, 212 compounds, and 61 assays for this target. The dominant activity type is IC50. CHEMBL4594438 is the current potency anchor at pChEMBL 10.3.

Use CHEMBL4594438 as the tractability anchor when discussing potency (pChEMBL 10.3).

Activity source · ChEMBL 36 via Core Engine
1 approved pChEMBL 10.3
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Structural capsid protein matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q76129, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why HIV infection is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

212
Total Compounds
61
Total Assays
1
Approved Drugs
IC50: 117.0, KI: 2.0, EC50: 8.0, KD: 66.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL4594438
 10.3 EC50 Approved
No preferred name
CHEMBL5619085
 9.7 EC50 —
No preferred name
CHEMBL5618694
 7.9 EC50 —
No preferred name
CHEMBL5618074
 7.7 EC50 —
No preferred name
CHEMBL4788393
 7.6 IC50 —

Approved Drugs

Structure Compound First Approval
LENACAPAVIR
CHEMBL4594438
 2022
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T13:45:33Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2366504